<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Red blood cell transfusion in infants and children: Administration and complications</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Red blood cell transfusion in infants and children: Administration and complications</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Red blood cell transfusion in infants and children: Administration and complications</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jun Teruya, MD, DSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Aaron Tobian, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Transfusions of red blood cells (RBCs) are given to children for a wide range of indications, including anemia due to congenital or acquired disease or blood loss from trauma, surgery, and/or frequent blood sampling. RBC transfusion has significant risks, including volume overload, transmission of infectious agents, and various immunologic consequences including transfusion reactions. Many of these complications can be avoided with careful administration of RBC transfusions.</p><p>The administration and complications of RBC transfusion in infants and children will be reviewed here. Other aspects of RBC transfusion in infants and children are discussed in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5910.html" rel="external">"Red blood cell transfusion in infants and children: Indications"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5935.html" rel="external">"Red blood cell transfusion in infants and children: Selection of blood products"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5041.html" rel="external">"Red blood cell (RBC) transfusions in the neonate"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7953.html" rel="external">"Pretransfusion testing for red blood cell transfusion"</a>.)</p><p></p><p class="headingAnchor" id="H719991029"><span class="h1">INFORMED CONSENT</span><span class="headingEndMark"> — </span>Except in emergency situations, specific informed consent for transfusion should be obtained and is required by the Joint Commission [<a href="#rid1">1</a>]. Parents or guardians are generally able to give this consent, although the additional assent of the child should also be considered. Teenagers in some states are able to give consent for their own medical treatment under certain circumstances.</p><p>The informed consent process should include <strong>all</strong> of the following components (see  <a class="medical medical_patient" href="/d/html/682.html" rel="external">"Patient education: Blood donation and transfusion (Beyond the Basics)"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Discussion of the expected benefits of transfusion</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Disclosure of the risks of transfusion (see <a class="local">'Complications'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Disclosure of the alternatives to transfusion, including no transfusion or, when appropriate, the option of medications such as iron or erythropoietin (EPO) </p><p></p><p>When the parent or guardian is unable or unwilling to give consent and clinicians feel that transfusion is medically necessary, guidance of the courts is often sought, with the appointment of a guardian specifically to give this permission.</p><p>The treatment of children of Jehovah's Witnesses should be individualized [<a href="#rid2">2</a>]. In general, the church is opposed to storage of blood for transfusion, but local groups and individuals within these groups take different positions about what kinds of hematologic support may be acceptable. In cases in which the child is placed at substantial medical risk because of parental nonconsent, court approval is often sought for transfusion. (See  <a class="medical medical_review" href="/d/html/7927.html" rel="external">"Approach to the patient who declines blood transfusion"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ADMINISTRATION</span></p><p class="headingAnchor" id="H3"><span class="h2">Patient identification</span><span class="headingEndMark"> — </span>As the infectious risks of transfusion continue to decline, more attention is being paid to other preventable hazards of transfusion, including known causes of transfusion-related deaths [<a href="#rid3">3</a>]. High on this list is a hemolytic transfusion reaction due to a misidentified patient or specimen, which occurs with a frequency greater than that of transfusion-associated transmission of HIV or hepatitis C [<a href="#rid3">3,4</a>]. (See  <a class="medical medical_review" href="/d/html/7932.html" rel="external">"Hemolytic transfusion reactions", section on 'Acute hemolytic transfusion reactions'</a>.)</p><p>It is not uncommon to have two patients on the same hospital floor with the same first and last name but different blood types who both require blood transfusion. As a result, all patients in the hospital, including children, should have armbands or similar methods of identification. These should be examined explicitly at the time specimens are drawn for blood bank testing and again immediately before each unit of blood is transfused. Careful attention should be paid to the labeling requirements of specimens for the blood bank [<a href="#rid5">5,6</a>]. Hospitals are increasingly using either a two-sample process (both drawn independently) for ABO/Rh typing prior to transfusion or electronic patient identification for sample labelling to decrease the risk of transfusion errors [<a href="#rid7">7,8</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Infusion pumps and catheter size</span><span class="headingEndMark"> — </span>Ordinary infusion pumps or roller infusion devices can be used to administer RBC transfusions without risk of causing hemolysis [<a href="#rid9">9</a>]. However, one practical concern in administering blood to children, particularly small infants, is the slow flow of blood products through small intravenous (IV) catheters. Blood under minimal pressure can be transfused through a 22-gauge catheter but will flow very slowly. Higher rates of flow can be achieved with pressure devices. Minimal hemolysis is caused by pressures of up to 300 mmHg and catheter sizes as small as 22 gauge [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Filters</span><span class="headingEndMark"> — </span>Blood must always be administered through a filter to remove small aggregates and blood clots that may have formed during storage [<a href="#rid11">11</a>]. The usual filter is 170 to 260 microns. These devices do not provide leukoreduction.</p><p>Many blood centers in the United States and other countries have adopted a policy of "universal leukoreduction," in which all RBC and apheresis platelet products are leukoreduced using a filtration process. Leukocyte reduction is usually performed at the time of collection. (See  <a class="medical medical_review" href="/d/html/5935.html" rel="external">"Red blood cell transfusion in infants and children: Selection of blood products", section on 'Leukoreduced red blood cells'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Volume</span><span class="headingEndMark"> — </span>The volume of blood to be transfused varies with the clinical situation. The usual transfusion volume is 10 to 15 mL/kg. Because infants have higher blood volume per kg compared with children, they tend to need transfusion volumes on the higher end of this range to achieve the desired hemoglobin concentration. If the hematocrit in the selected RBC product is approximately 65 percent, this volume will usually raise the hemoglobin concentration by 2 to 3 g/dL or the hematocrit by 6 to 9 percent [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/5935.html" rel="external">"Red blood cell transfusion in infants and children: Selection of blood products", section on 'Red blood cells'</a>.)</p><p>In neonates, the small volumes require the use of special equipment, which is discussed separately. (See  <a class="medical medical_review" href="/d/html/5041.html" rel="external">"Red blood cell (RBC) transfusions in the neonate", section on 'Administration'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Infusion duration</span><span class="headingEndMark"> — </span>Blood issued for transfusion should be infused within four hours. More rapid infusion is appropriate when there is acute blood loss resulting in compromised tissue perfusion. (See  <a class="medical medical_review" href="/d/html/6571.html" rel="external">"Trauma management: Approach to the unstable child", section on 'Blood products'</a>.)</p><p>If the transfusion will take longer than four hours because of slow flow or other issues, the blood bank can divide the unit into smaller aliquots so that each can be transfused within four hours. In special circumstances, such as for the operating room or a remote clinic, the blood bank may issue RBC units in coolers that have been validated to maintain the appropriate storage temperature.</p><p>A transfusion rate of approximately 2.5 mL/kg/hour usually avoids circulatory overload. Thus, an RBC transfusion of 10 mL/kg usually is transfused over a four-hour period. Patients deemed to be at risk for volume overload (such as those with impaired cardiac function) can be transfused at a slower rate of 1 mL/kg/hour.</p><p class="headingAnchor" id="H8"><span class="h2">Compatible fluids</span><span class="headingEndMark"> — </span>IV normal <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> (0.9% sodium) is compatible with RBCs and can be given concomitantly through the same tubing if IV fluid is required for hydration or to maintain the patency of the catheter. ABO-compatible plasma and albumin are also compatible with RBCs. No other IV solutions or medications should be administered through the same tubing concurrently with the RBC units [<a href="#rid11">11</a>]. Exceptions can be made for products that have explicit approval for compatibility with RBCs in the package insert approved by the US Food and Drug Administration. Such approval has been granted for some isotonic, calcium-free electrolyte solutions.</p><p>Commonly used IV solutions that are <strong>incompatible</strong> with RBCs include:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypotonic solutions (including 5% aqueous dextrose and 5% dextrose in 0.225% <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a>) because they can cause hemolysis</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="108442" href="/d/drug information/108442.html" rel="external">Lactated Ringer</a> solutions or other calcium-containing solutions because calcium in these products reverses the anticoagulation in the RBC preparation, causing clotting</p><p></p><p>If a single line is being used, the tubing should be flushed carefully before and after blood administration if a potentially incompatible fluid has been infused.</p><p>Additional discussion regarding compatibility of IV fluids and medications with RBC transfusion is provided separately. (See  <a class="medical medical_review" href="/d/html/7939.html" rel="external">"Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Compatible fluids'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Blood warmers</span><span class="headingEndMark"> — </span>RBCs are preserved in the blood bank at 1 to 6°C. For a slow transfusion, this temperature may not pose a problem. However, the use of a blood warmer is recommended in the following clinical settings:</p><p class="bulletIndent1"><span class="glyph">●</span>Unstable infants</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who require rapid transfusion of a large amount of blood (&gt;15 mL/kg/hour)</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who require exchange transfusions</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with cold agglutinin disease (see  <a class="medical medical_review" href="/d/html/7084.html" rel="external">"Cold agglutinin disease", section on 'Transfusions'</a>)</p><p></p><p>If the blood requires warming, it is warmed at the time of transfusion using an approved and calibrated device. These devices must be monitored since excessive warming can cause hemolysis. Blood should never be warmed in an uncontrolled way.</p><p class="headingAnchor" id="H10"><span class="h2">Exchange transfusion</span><span class="headingEndMark"> — </span>RBC exchange can be performed with an automated apheresis instrument, unless the patient is very small. The automated controls of these instruments are quite accurate in providing the desired target hemoglobin value, and their utility has been demonstrated in a number of studies [<a href="#rid13">13,14</a>]. RBC priming of the instrument is recommended if the extracorporeal volume is more than 10 to 15 percent of the estimated total blood volume (eg, children weighing &lt;10 kg and those with severe anemia) [<a href="#rid15">15</a>]. </p><p>Most instruments require two sites of vascular access for draw and return; this can be problematic in children who have poor venous access. In emergency settings, double-lumen central catheters, commonly used for hemodialysis, can be placed in the femoral vein. For long-term venous access for repeated exchanges, a surgically implanted port or central venous catheter may be required.</p><p>Exchange transfusion in neonates is discussed separately. (See  <a class="medical medical_review" href="/d/html/121592.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Escalation of care", section on 'Exchange transfusion'</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Undesirable sequelae of transfusion may be divided into infectious and noninfectious categories. As transfusion-transmitted infections have dramatically decreased since the 1980s and 1990s, the most common adverse events in the modern era are noninfectious transfusion reactions [<a href="#rid16">16,17</a>].</p><p>The following is a brief review of the different complications from blood transfusions, each of which is discussed in detail elsewhere.</p><p class="headingAnchor" id="H13"><span class="h2">Infection</span><span class="headingEndMark"> — </span>All donated blood is extensively screened for transfusion-transmitted infections; as a result, the risk of acquiring infection is extremely low  (<a class="graphic graphic_table graphicRef69661" href="/d/graphic/69661.html" rel="external">table 1</a>). The table lists the infectious agents for which donated blood is routinely screened in the United States  (<a class="graphic graphic_table graphicRef106595" href="/d/graphic/106595.html" rel="external">table 2</a>). A more complete discussion on the screening for transfusion-transmitted infection is found elsewhere. (See  <a class="medical medical_review" href="/d/html/7946.html" rel="external">"Blood donor screening: Laboratory testing", section on 'Infectious disease screening and surveillance'</a>.)</p><p>Residual risk remains largely from "window period" donations, during the time when antigens and/or antibodies are of such low level as to be undetectable by current techniques. </p><p>The risk of bacterial contamination of blood products is greater than the risk of viral transmission, especially for platelet products since they are stored at room temperature [<a href="#rid16">16,18</a>]. Bacterial contamination of blood products can occur at the time of collection or because the donor had occult bacteremia at the time of donation. Temperature elevation, hypotension, or other signs of sepsis should be investigated carefully in a patient who has received a transfusion. (See  <a class="medical medical_review" href="/d/html/7950.html" rel="external">"Blood donor screening: Medical history", section on 'General symptoms of active infection'</a> and  <a class="medical medical_review" href="/d/html/3805.html" rel="external">"Transfusion-transmitted bacterial infection"</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Transfusion reaction</span><span class="headingEndMark"> — </span>Transfusion reactions occur in approximately 1 percent of children who received RBC transfusions [<a href="#rid19">19</a>].</p><p>These reactions are briefly reviewed here and are discussed in greater detail elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute hemolytic reactions</strong> – Acute hemolytic transfusion reactions usually result from transfusion of ABO-incompatible RBCs due to clerical errors. This complication is best prevented, rather than treated, by meticulous attention to patient and sample identification. Treatment is supportive. (See <a class="local">'Patient identification'</a> above and  <a class="medical medical_review" href="/d/html/7932.html" rel="external">"Hemolytic transfusion reactions", section on 'Acute hemolytic transfusion reactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delayed hemolytic reactions</strong> – Delayed hemolysis results when the patient produces an antibody days following a blood transfusion or by anamnestic response. It presents 2 to 10 days following transfusion as jaundice and/or an unexpected fall in hemoglobin. A delayed hemolytic transfusion reaction is confirmed by repeat antibody screening of the patient's plasma, which demonstrates the presence of a specific alloantibody that was not previously present or identified. Positive direct antiglobulin test for immunoglobulin G (IgG) with a positive eluate against the corresponding antigen will confirm the diagnosis. Many RBC antibodies can cause delayed hemolysis, such as anti-C, anti-E, anti-K, anti-Jka and anti-Jkb. Subsequent RBC transfusions should utilize blood that tests negative for the newly identified antigen. (See  <a class="medical medical_review" href="/d/html/7932.html" rel="external">"Hemolytic transfusion reactions", section on 'Delayed hemolytic transfusion reactions and delayed serologic transfusion reactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Febrile reactions</strong> – Febrile reactions not due to hemolysis are usually related to the presence of cytokines produced by passenger leukocytes. Treatment includes stopping the transfusion and excluding a hemolytic reaction or sepsis as the cause of fever. Antipyretic therapy is given for symptomatic relief. These reactions are reduced with leukoreduction. (See  <a class="medical medical_review" href="/d/html/7947.html" rel="external">"Immunologic transfusion reactions", section on 'Febrile nonhemolytic transfusion reactions'</a> and  <a class="medical medical_review" href="/d/html/5935.html" rel="external">"Red blood cell transfusion in infants and children: Selection of blood products", section on 'Leukoreduced red blood cells'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allergic and anaphylactic reactions</strong> – An anaphylactic, allergic, or anaphylactoid reaction to a blood transfusion can vary in severity from mild hives and itching to fatal anaphylaxis. While more common with plasma and platelet transfusions, these reactions also may occur following RBC transfusion. Treatment is supportive, usually including antihistamines. (See  <a class="medical medical_review" href="/d/html/7947.html" rel="external">"Immunologic transfusion reactions", section on 'Allergic reactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transfusion-associated acute lung injury (TRALI)</strong> – TRALI is an important cause of transfusion-related mortality and should be suspected when dyspnea, bilateral noncardiogenic pulmonary edema, hypotension, and fever occur within six hours of completion of transfusion. It is due primarily to the interaction between leukocytes from the recipient and anti-human leukocyte antigen antibodies or antigranulocyte antibodies from the donor. Treatment is supportive. TRALI is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/7926.html" rel="external">"Transfusion-related acute lung injury (TRALI)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transfusion-associated circulatory overload (TACO) – </strong>TACO may occur in children, although it is less common in children compared with adults. In the modern era, TACO is the leading cause of transfusion-related mortality [<a href="#rid20">20</a>]. Manifestations may begin near the end or within six hours after the transfusion. Patients should be monitored closely during this time period for suggestive signs and symptoms, including dyspnea, orthopnea, tachycardia, and a wide pulse pressure, often with hypertension. Patients deemed to be at risk for volume overload (such as those with impaired cardiac function) can be transfused at a slower rate (see <a class="local">'Infusion duration'</a> above). Diuretic therapy (eg, <a class="drug drug_pediatric" data-topicid="13329" href="/d/drug information/13329.html" rel="external">furosemide</a> 0.5 to 1 mg/kg/dose) may be used as a preventive measure and/or for treatment of symptoms. TACO is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/7919.html" rel="external">"Transfusion-associated circulatory overload (TACO)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distinguishing between TRALI and TACO</strong> – The symptoms of TRALI and TACO are similar. Distinguishing features are as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>TACO usually is associated with transfusion of a large volume of blood or a high rate of infusion; TRALI may occur with relatively small volumes at a slow rate.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypertension is commonly seen in TACO but is uncommon in TRALI.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fever is typically absent in TACO, whereas TRALI is often associated with fever.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Brain natriuretic peptide is often elevated in patients with TACO, whereas it may be normal in TRALI [<a href="#rid21">21,22</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with TACO usually respond well to diuretic therapy; the response to diuretic therapy in patients with TRALI is variable.</p><p></p><p class="headingAnchor" id="H16"><span class="h2">Metabolic toxicity</span><span class="headingEndMark"> — </span>Metabolic toxicities from RBC transfusion include the following [<a href="#rid23">23-29</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypocalcemia and/or hypoglycemia, which results from the infused citrate in the preservative solution. Newborns are at particular risk for this complication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperkalemia in patients who receive large volumes of blood (eg, exchange or massive transfusions) or rapid transfusion of irradiated blood (radiation increases cellular leakage of potassium). Children who receive large quantities of blood infused through a central line, as in exchange transfusions or massive transfusions, are at particular risk for hyperkalemia [<a href="#rid30">30-34</a>]. Some institutions will provide either fresh RBCs or washed RBCs if hyperkalemia is a concern. (See  <a class="medical medical_review" href="/d/html/7939.html" rel="external">"Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Hyperkalemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinically significant accumulation of <a class="drug drug_pediatric" data-topicid="12570" href="/d/drug information/12570.html" rel="external">mannitol</a> (a component of preservative solutions) in neonates who receive large volumes of blood may result in an osmotic diuresis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinically significant accumulation of adenine (a component of preservative solutions) in young infants who receive large volumes of blood may cause nephrotoxicity.</p><p></p><p class="headingAnchor" id="H17"><span class="h2">Graft-versus-host disease</span><span class="headingEndMark"> — </span>Transfusion-associated graft-versus-host disease (TA-GVHD) is almost universally fatal and can be prevented by the use of irradiated products. It is caused by viable, competent donor lymphocytes that are transfused into a patient whose immune system either does not recognize the cells as foreign or does not have the capacity to destroy them. To reduce the risk of TA-GVHD in patients requiring RBC transfusion, it is important to consider the immune status of the child and use irradiated products if indicated  (<a class="graphic graphic_table graphicRef119039" href="/d/graphic/119039.html" rel="external">table 3</a>). Patients who are at risk for TA-GVHD include premature, low birth weight infants; infants and children with primary immunodeficiencies; organ transplant recipients; and patients receiving chemotherapy or other immunosuppressive therapy. (See  <a class="medical medical_review" href="/d/html/7928.html" rel="external">"Transfusion-associated graft-versus-host disease"</a> and  <a class="medical medical_review" href="/d/html/5935.html" rel="external">"Red blood cell transfusion in infants and children: Selection of blood products", section on 'Irradiated red blood cells'</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Iron overload</span><span class="headingEndMark"> — </span>Iron overload can be a significant problem in children who are transfused chronically. As an example, patients with thalassemia major can develop heart failure or fatal arrhythmia due to deposition of cardiac iron if they are not treated with an iron chelator. The excess iron from transfusions is compounded by increased iron absorption due to ineffective erythropoiesis.</p><p>Children who are at risk for iron overload can be treated with iron chelation therapy. Iron chelation therapy can reduce the damage produced by the lifelong need for RBC transfusions in these children. In addition, exchange transfusion rather than simple transfusion has been used in children with sickle cell disease, partly to reduce the risk of iron overload. (See  <a class="medical medical_review" href="/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload", section on 'Transfusional iron overload'</a> and  <a class="medical medical_review" href="/d/html/128123.html" rel="external">"Transfusion in sickle cell disease: Management of complications including iron overload", section on 'Excessive iron stores'</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">MEASURES TO REDUCE TRANSFUSION</span></p><p class="headingAnchor" id="H20"><span class="h2">Erythropoietin</span><span class="headingEndMark"> — </span>Use of recombinant human erythropoietin (EPO) to increase the patient's endogenous production of RBCs has been investigated, but its role in reducing blood transfusions in infants and children remains limited.</p><p>The possible efficacy of EPO has been studied in the following clinical settings:</p><p class="bulletIndent1"><span class="glyph">●</span>Premature infants – Although EPO has been reported to reduce the number of transfusions in premature infants, it does not generally eliminate the need for transfusion. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/4962.html" rel="external">"Anemia of prematurity (AOP)", section on 'Erythropoiesis stimulating agents (ESAs)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children with cancer – Reports vary on whether EPO is effective in reducing blood transfusions in children with cancer [<a href="#rid35">35-38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children with chronic renal failure – EPO is a standard therapy for the anemia associated with chronic renal failure, which is due to reduced EPO production by the kidney. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Anemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Myelodysplastic syndrome and bone marrow failure syndromes – EPO plays a role in the management of patients with anemia due to myelodysplastic syndrome, but it is not effective in treating the anemia associated with bone marrow failure syndromes (eg, aplastic anemia, Diamond-Blackfan anemia). These conditions are discussed separately. (See  <a class="medical medical_review" href="/d/html/15776.html" rel="external">"Myelodysplastic syndromes/neoplasms (MDS): Management of hematologic complications in lower-risk MDS", section on 'Erythropoiesis-stimulating agents'</a> and  <a class="medical medical_review" href="/d/html/131283.html" rel="external">"Diamond-Blackfan anemia"</a> and  <a class="medical medical_review" href="/d/html/5923.html" rel="external">"Treatment of acquired aplastic anemia in children and adolescents"</a>.)</p><p></p><p class="headingAnchor" id="H21"><span class="h2">Artificial oxygen carriers</span><span class="headingEndMark"> — </span>"Artificial blood" (ie, oxygen therapeutics or oxygen carriers) are substances that can fulfill some of the oxygen-carrying function of the RBC and have been under investigation as a measure to reduce transfusion. They consist of either noncellular hemoglobin solutions stabilized to prevent immediate removal by the kidneys or perfluorocarbon emulsions capable of transporting dissolved oxygen. There are no artificial oxygen carriers that are approved by the US Food and Drug Administration, but they can be used on compassionate use. (See  <a class="medical medical_review" href="/d/html/7923.html" rel="external">"Oxygen carriers as alternatives to red blood cell transfusion"</a>.)</p><p class="headingAnchor" id="H2038309750"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/120167.html" rel="external">"Society guideline links: Transfusion and patient blood management"</a>.)</p><p class="headingAnchor" id="H17472421"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Informed consent</strong> – Except in emergency situations, specific informed consent for transfusion should be obtained prior to administration of red blood cell (RBC) transfusion. The informed consent process should include disclosure of the expected benefits of transfusion; potential risks; and alternatives, including no transfusion or, when appropriate, the option of medications such as iron or erythropoietin (EPO). (See <a class="local">'Informed consent'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>RBC transfusion volume and infusion duration</strong> – The usual RBC transfusion volume in children is 10 to 15 mL/kg; this volume is expected to raise the hemoglobin concentration by 2 to 3 g/dL. To avoid volume overload, the transfusion should be given slowly, at approximately 2.5 mL/kg/hour (10 mL/kg over four hours). If the transfusion will take longer than four hours because of slow flow or other issues, the blood bank can issue the transfusion in smaller aliquots so that each can be given over less than four hours. (See <a class="local">'Volume'</a> above and <a class="local">'Infusion duration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infectious screening</strong> – In the United States, each unit of blood is screened for a number of infections, as summarized in the<em> </em> (<a class="graphic graphic_table graphicRef106595" href="/d/graphic/106595.html" rel="external">table 2</a>) and discussed separately. (See  <a class="medical medical_review" href="/d/html/7946.html" rel="external">"Blood donor screening: Laboratory testing", section on 'Infectious disease screening and surveillance'</a>.)</p><p></p><p class="bulletIndent1">Residual risk remains largely from "window period" donations, during the time when antigen and/or antibody are of such low level as to be undetectable by current techniques. This risk is very low. (See <a class="local">'Infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transfusion reactions</strong> – Transfusion reactions occur in approximately 1 percent of children who received transfusions. Types of transfusion reactions include (see <a class="local">'Transfusion reaction'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute hemolytic reactions, which usually result from the mistransfusion of ABO-incompatible RBCs and are best prevented by meticulous attention to patient and sample identification. (See <a class="local">'Patient identification'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Delayed hemolytic reactions, which present 2 to 10 days following transfusion as jaundice and/or an unexpected fall in hemoglobin. These reactions result when the patient produces an antibody during the days following a blood transfusion or by anamnestic response. (See  <a class="medical medical_review" href="/d/html/7932.html" rel="external">"Hemolytic transfusion reactions", section on 'Delayed hemolytic transfusion reactions and delayed serologic transfusion reactions'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Febrile reactions are usually related to the presence of cytokines produced by passenger leukocytes and can be reduced with leukoreduction. Treatment includes stopping the transfusion, excluding a hemolytic reaction or other causes of fever, and administering antipyretic therapy for symptomatic relief. (See  <a class="medical medical_review" href="/d/html/7947.html" rel="external">"Immunologic transfusion reactions", section on 'Febrile nonhemolytic transfusion reactions'</a> and  <a class="medical medical_review" href="/d/html/5935.html" rel="external">"Red blood cell transfusion in infants and children: Selection of blood products", section on 'Leukoreduced red blood cells'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Allergic and anaphylactic reactions can vary in severity from mild hives and itching to fatal anaphylaxis. Treatment is supportive and often includes antihistamines. (See  <a class="medical medical_review" href="/d/html/7947.html" rel="external">"Immunologic transfusion reactions", section on 'Allergic reactions'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Transfusion-associated acute lung injury (TRALI) is an important cause of transfusion-related mortality and should be suspected if a patient develops dyspnea, pulmonary edema, hypotension, and fever within six hours of a transfusion. (See  <a class="medical medical_review" href="/d/html/7926.html" rel="external">"Transfusion-related acute lung injury (TRALI)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Transfusion-associated circulatory overload (TACO) may occur, particularly in children with impaired cardiac function. Symptoms typically begin near the end of the transfusion or within the subsequent six hours. Patients should be monitored closely during this time period for suggestive signs and symptoms, including dyspnea, orthopnea, tachycardia, and a wide pulse pressure, often with hypertension. (See  <a class="medical medical_review" href="/d/html/7919.html" rel="external">"Transfusion-associated circulatory overload (TACO)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolic side effects</strong> – Metabolic derangements that can result from RBC transfusion include hypocalcemia, hypoglycemia, and hyperkalemia. Neonates are at risk for accumulation of <a class="drug drug_pediatric" data-topicid="12570" href="/d/drug information/12570.html" rel="external">mannitol</a> and/or adenine, which can cause an osmotic diuresis and/or nephrotoxicity. (See <a class="local">'Metabolic toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transfusion-associated graft-versus-host disease (TA-GVHD)</strong> – TA-GVHD is almost universally fatal and can be prevented by the use of irradiated products. Patients who are at risk for TA-GVHD (and hence should receive irradiated products) include premature, low birth weight infants; infants and children with primary immunodeficiencies; organ transplant recipients; and patients receiving chemotherapy or other immunosuppressive therapy  (<a class="graphic graphic_table graphicRef119039" href="/d/graphic/119039.html" rel="external">table 3</a>). (See <a class="local">'Graft-versus-host disease'</a> above and  <a class="medical medical_review" href="/d/html/7928.html" rel="external">"Transfusion-associated graft-versus-host disease"</a> and  <a class="medical medical_review" href="/d/html/5935.html" rel="external">"Red blood cell transfusion in infants and children: Selection of blood products", section on 'Irradiated red blood cells'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sazama K. Practical issues in informed consent for transfusion. Am J Clin Pathol 1997; 107:S72.</a></li><li><a class="nounderline abstract_t">Bennett DR, Shulman IA. Practical issues when confronting the patient who refuses blood transfusion therapy. Am J Clin Pathol 1997; 107:S23.</a></li><li><a class="nounderline abstract_t">Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990; 30:583.</a></li><li><a class="nounderline abstract_t">Strong DM, Katz L. Blood-bank testing for infectious diseases: how safe is blood transfusion? Trends Mol Med 2002; 8:355.</a></li><li class="breakAll">Rossmann SN. Specimen labeling for compatibility testing. American Association of Blood Banks, Bethesda 2002.</li><li><a class="nounderline abstract_t">Lumadue JA, Boyd JS, Ness PM. Adherence to a strict specimen-labeling policy decreases the incidence of erroneous blood grouping of blood bank specimens. Transfusion 1997; 37:1169.</a></li><li><a class="nounderline abstract_t">Glisch C, Jawa Z, Brener A, et al. Evaluation of a two-sample process for prevention of ABO mistransfusions in a high volume academic hospital. BMJ Open Qual 2018; 7:e000270.</a></li><li><a class="nounderline abstract_t">Kaufman RM, Dinh A, Cohn CS, et al. Electronic patient identification for sample labeling reduces wrong blood in tube errors. Transfusion 2019; 59:972.</a></li><li><a class="nounderline abstract_t">Ciavarella D, Snyder E. Clinical use of blood transfusion devices. Transfus Med Rev 1988; 2:95.</a></li><li><a class="nounderline abstract_t">Frelich R, Ellis MH. The effect of external pressure, catheter gauge, and storage time on hemolysis in RBC transfusion. Transfusion 2001; 41:799.</a></li><li class="breakAll">American Association of Blood Banks. Standards for Blood Banks and Transfusion Services, 32nd ed, American Association of Blood Banks, 2020.</li><li><a class="nounderline abstract_t">Davies P, Robertson S, Hegde S, et al. Calculating the required transfusion volume in children. Transfusion 2007; 47:212.</a></li><li><a class="nounderline abstract_t">Lawson SE, Oakley S, Smith NA, Bareford D. Red cell exchange in sickle cell disease. Clin Lab Haematol 1999; 21:99.</a></li><li><a class="nounderline abstract_t">Adams DM, Schultz WH, Ware RE, Kinney TR. Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients. J Pediatr Hematol Oncol 1996; 18:46.</a></li><li><a class="nounderline abstract_t">Kim HC. Therapeutic pediatric apheresis. J Clin Apher 2000; 15:129.</a></li><li><a class="nounderline abstract_t">Busch MP, Bloch EM, Kleinman S. Prevention of transfusion-transmitted infections. Blood 2019; 133:1854.</a></li><li><a class="nounderline abstract_t">Goel R, Tobian AAR, Shaz BH. Noninfectious transfusion-associated adverse events and their mitigation strategies. Blood 2019; 133:1831.</a></li><li><a class="nounderline abstract_t">Erony SM, Marshall CE, Gehrie EA, et al. The epidemiology of bacterial culture-positive and septic transfusion reactions at a large tertiary academic center: 2009 to 2016. Transfusion 2018; 58:1933.</a></li><li><a class="nounderline abstract_t">Slonim AD, Joseph JG, Turenne WM, et al. Blood transfusions in children: a multi-institutional analysis of practices and complications. Transfusion 2008; 48:73.</a></li><li class="breakAll">US Food and Drug Administration. Fatalities Reported to FDA Following Blood Collection and Transfusion: Annual Summary for Fiscal Year 2018. Available at: https://www.fda.gov/media/136907/download (Accessed on May 09, 2021).</li><li><a class="nounderline abstract_t">Zhou L, Giacherio D, Cooling L, Davenport RD. Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload. Transfusion 2005; 45:1056.</a></li><li><a class="nounderline abstract_t">Tobian AA, Sokoll LJ, Tisch DJ, et al. N-terminal pro-brain natriuretic peptide is a useful diagnostic marker for transfusion-associated circulatory overload. Transfusion 2008; 48:1143.</a></li><li><a class="nounderline abstract_t">Jackson JC. Adverse events associated with exchange transfusion in healthy and ill newborns. Pediatrics 1997; 99:E7.</a></li><li><a class="nounderline abstract_t">Roseff SD, Luban NL, Manno CS. Guidelines for assessing appropriateness of pediatric transfusion. Transfusion 2002; 42:1398.</a></li><li><a class="nounderline abstract_t">Jain R, Jarosz C. Safety and efficacy of AS-1 red blood cell use in neonates. Transfus Apher Sci 2001; 24:111.</a></li><li><a class="nounderline abstract_t">Strauss RG, Sacher RA, Blazina JF, et al. Commentary on small-volume red cell transfusions for neonatal patients. Transfusion 1990; 30:565.</a></li><li><a class="nounderline abstract_t">Rock G, Poon A, Haddad S, et al. Nutricel as an additive solution for neonatal transfusion. Transfus Sci 1999; 20:29.</a></li><li><a class="nounderline abstract_t">Strauss RG, Burmeister LF, Johnson K, et al. Feasibility and safety of AS-3 red blood cells for neonatal transfusions. J Pediatr 2000; 136:215.</a></li><li><a class="nounderline abstract_t">Luban NL, Strauss RG, Hume HA. Commentary on the safety of red cells preserved in extended-storage media for neonatal transfusions. Transfusion 1991; 31:229.</a></li><li><a class="nounderline abstract_t">Brown KA, Bissonnette B, MacDonald M, Poon AO. Hyperkalaemia during massive blood transfusion in paediatric craniofacial surgery. Can J Anaesth 1990; 37:401.</a></li><li><a class="nounderline abstract_t">Carvalho B, Quiney NF. 'Near-miss' hyperkalaemic cardiac arrest associated with rapid blood transfusion. Anaesthesia 1999; 54:1094.</a></li><li><a class="nounderline abstract_t">Hall TL, Barnes A, Miller JR, et al. Neonatal mortality following transfusion of red cells with high plasma potassium levels. Transfusion 1993; 33:606.</a></li><li><a class="nounderline abstract_t">Horsey PJ. Hyperkalaemia associated with transfusion of plasma reduced blood. Anaesthesia 2000; 55:294.</a></li><li><a class="nounderline abstract_t">Baz EM, Kanazi GE, Mahfouz RA, Obeid MY. An unusual case of hyperkalaemia-induced cardiac arrest in a paediatric patient during transfusion of a 'fresh' 6-day-old blood unit. Transfus Med 2002; 12:383.</a></li><li><a class="nounderline abstract_t">Wagner LM, Billups CA, Furman WL, et al. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial. J Clin Oncol 2004; 22:1886.</a></li><li><a class="nounderline abstract_t">Ludwig H, Sundal E, Pecherstorfer M, et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 1995; 76:2319.</a></li><li><a class="nounderline abstract_t">León P, Jiménez M, Barona P, Sierrasesúmaga L. Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors. Med Pediatr Oncol 1998; 30:110.</a></li><li><a class="nounderline abstract_t">Porter JC, Leahey A, Polise K, et al. Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double-blind, placebo-controlled trial. J Pediatr 1996; 129:656.</a></li></ol></div><div id="topicVersionRevision">Topic 5938 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9124233" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Practical issues in informed consent for transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9124226" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Practical issues when confronting the patient who refuses blood transfusion therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2402771" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Reports of 355 transfusion-associated deaths: 1976 through 1985.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12114117" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Blood-bank testing for infectious diseases: how safe is blood transfusion?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12114117" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Blood-bank testing for infectious diseases: how safe is blood transfusion?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9426641" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Adherence to a strict specimen-labeling policy decreases the incidence of erroneous blood grouping of blood bank specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30057954" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evaluation of a two-sample process for prevention of ABO mistransfusions in a high volume academic hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30549289" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Electronic patient identification for sample labeling reduces wrong blood in tube errors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2980083" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical use of blood transfusion devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11399823" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The effect of external pressure, catheter gauge, and storage time on hemolysis in RBC transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11399823" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The effect of external pressure, catheter gauge, and storage time on hemolysis in RBC transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17302766" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Calculating the required transfusion volume in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10342068" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Red cell exchange in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8556370" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10767053" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Therapeutic pediatric apheresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30808637" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevention of transfusion-transmitted infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30808635" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Noninfectious transfusion-associated adverse events and their mitigation strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30153333" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The epidemiology of bacterial culture-positive and septic transfusion reactions at a large tertiary academic center: 2009 to 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17894792" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Blood transfusions in children: a multi-institutional analysis of practices and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17894792" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Blood transfusions in children: a multi-institutional analysis of practices and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15987348" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18298592" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : N-terminal pro-brain natriuretic peptide is a useful diagnostic marker for transfusion-associated circulatory overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9113964" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Adverse events associated with exchange transfusion in healthy and ill newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12421212" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Guidelines for assessing appropriateness of pediatric transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11501569" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Safety and efficacy of AS-1 red blood cell use in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2378026" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Commentary on small-volume red cell transfusions for neonatal patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10621556" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Nutricel as an additive solution for neonatal transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10657828" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Feasibility and safety of AS-3 red blood cells for neonatal transfusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1900648" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Commentary on the safety of red cells preserved in extended-storage media for neonatal transfusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2340608" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hyperkalaemia during massive blood transfusion in paediatric craniofacial surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10540099" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : 'Near-miss' hyperkalaemic cardiac arrest associated with rapid blood transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8333025" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Neonatal mortality following transfusion of red cells with high plasma potassium levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10744565" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Hyperkalaemia associated with transfusion of plasma reduced blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12473156" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : An unusual case of hyperkalaemia-induced cardiac arrest in a paediatric patient during transfusion of a 'fresh' 6-day-old blood unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15143081" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8635038" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9403020" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8917229" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
